

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent:	J-Lat Full Length Cells (8.4)
Catalog Number:	9847
Lot Number:	190029
Release Category:	C
Provided:	800 uL of cells
	Post thaw cell count = 6.4×10^6 cells/Vial
	Post thaw cell viability = 59 %
	Cell viability increased to 94% after 14 days in culture.
Cell Type:	Human T cell lymphoblast
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%; 2mM GlutaMAX™
Freeze Medium:	Donor Provided Freeze Media: fetal bovine serum, 90 %; DMSO, 10%
	Current Freeze Media:Gibco Recovery™ Cell Culture Freezing Medium.
Morphology:	Lymphocytic, Suspension Cell Line
Sterility:	Negative for mycoplasma, bacteria, and fungi
Description:	This is a Jurkat-based cell line containing a full-length integrated HIV-1 genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in env.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Special Characteristics:	Jurkat cells were infected with the packaged retroviral construct HIV-R7/E-/GFP, which is full length HIV-1 genome with a non-functional Env due to a frameshift, and GFP in place of the Nef gene.
	Full-length constructs secrete incomplete viral particles (capsids). The cells express low to undetectable levels of GFP under basal conditions. Suited to study HIV latency and reactivation.
	The clones in this series are: 6.3 (cat# 9846), 8.4 (cat# 9847), 9.2 (cat# 9848), 10.6 (cat# 9849), and 15.4 (cat# 9850).
	Please see Table I in the reference publication for differences between these clones in GFP and p24 expression upon stimulation with TNF-a
Recommended Storage:	Keep the reagent in liquid nitrogen.
Contributor:	Dr. Eric Verdin.
References:	Jordan, A., Bisgrove, D., & Verdin, E. (2003). HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 22(8), 1868-1877. doi:10.1093/emboj/cdg188 PUBMED
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Full Length Cells (8.4) from Dr. Eric Verdin (cat#9847)." Also include the reference cited above in any publication.
	These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.
	Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: <u>veronica.viray@gladstone.ucsf.edu</u> , before the reagent can be released. Please specify the name and a description of the intended use of the reagent.
Last Updated	November 16, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.